Q32 BioFRA:DB0 -0.18%17 1-Year ROIIC % is -1,731.51 as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,342 Biotechnology companies, Q32 Bio ranks worse than 94.63% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Q32 Bio's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -1,731.51%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Q32 Bio's 1-Year ROIIC % or its related term are showing as below:
FRA:DB0's 1-Year ROIIC % is ranked worse than 94.63% of 1342
companies
in the Biotechnology industry
Industry Median: -8.825
vs FRA:DB0: -1731.51
Q32 Bio (FRA:DB0) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Q32 Bio 1-Year ROIIC % Related Terms
Q32 Bio 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Q32 Bio's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DB0 vs CAMP, CDXS, KROS: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Q32 Bio's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Q32 Bio's 1-Year ROIIC % falls into.
Q32 Bio's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 18.094 (Mar. 2026) - -58.781 (Mar. 2025) )
/
( 12.492 (Mar. 2026) - 17.894 (Mar. 2025) )
=
76.875
/
-5.402
=
-1,423.08%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Q32 Bio (FRA:DB0) has a 1-Year ROIIC % of -1,731.51 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #1270 out of 1342 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Q32 Bio's 1-Year ROIIC % too high?
Q32 Bio's current 1-Year ROIIC % is -1,731.51. Based on the distribution chart, Q32 Bio ranks #1270 out of 1342 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's 1-Year ROIIC % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #1270 out of 1342 companies for 1-Year ROIIC %. This places Q32 Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Q32 Bio and its competitors. Q32 Bio's current 1-Year ROIIC % is -1,731.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current 1-Year ROIIC % of -1,731.51. The current 1-Year ROIIC % is -1,731.51. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current 1-Year ROIIC % is -1,731.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for FRA:DB0
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
